Gilead Sciences Invests $32 Billion in US Manufacturing Hub

Gilead Sciences is investing $32 billion in the US, including building a manufacturing hub. The company specializes in developing and marketing therapeutic products, with net sales primarily coming from the sale of drugs for treating HIV, oncology diseases, hepatitis B virus, Ebola virus, and other conditions. Net sales are distributed across the US, Europe, and other regions.

Gilead Sciences, a prominent biopharmaceutical company, has taken a significant step towards bolstering its U.S. presence by breaking ground on a new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) in Foster City, California. This strategic move is part of the company's broader $32 billion investment plan aimed at driving growth and innovation across virology, oncology, and inflammation, with a focus on biologics [1].

The new facility, designed to be a hub for innovation and collaboration, is expected to generate over $43 billion in economic value nationwide. It will feature advanced digital infrastructure, autonomous robotics, and real-time digital monitoring, positioning it as one of the most AI-enabled centers in the biopharma industry [1]. This investment aligns with Gilead's long-term strategy to expand research and manufacturing, create high-quality jobs, and enhance equitable access to healthcare in the United States [1].

Gilead Sciences' net sales are primarily driven by the sale of drugs for treating HIV, oncology diseases, hepatitis B virus, Ebola virus, and other conditions. The company's revenue is distributed across the U.S., Europe, and other regions, with the U.S. accounting for 71.6% of total sales [2, 3].

The groundbreaking of the NTDC is part of a larger expansion at Gilead's Foster City headquarters, which includes the development of two other state-of-the-art facilities: a new research building and a biologics manufacturing facility. These investments build on Gilead's history of U.S. investment, with more than $15 billion over the last decade, and reinforce its role as a key player in the U.S. biopharmaceutical industry [1].

The event was attended by Gilead leadership, including Daniel O’Day, Chairman and CEO, and distinguished guests such as California Lieutenant Governor Eleni Kounalakis, Tim Scott, CEO of Biocom, and Supervisor Noelia Corzo of San Mateo County Board of Supervisors [1].

References:
[1] https://www.morningstar.com/news/business-wire/20250903363682/gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-us-growth-and-innovation-strategy
[2] https://www.marketscreener.com/news/gilead-sciences-insider-sold-shares-worth-1-136-300-according-to-a-recent-sec-filing-ce7c50dddc8df020
[3] https://www.marketscreener.com/news/gilead-starts-building-manufacturing-hub-under-32-billion-planned-us-investments-ce7d59dbdb80f220